160 related articles for article (PubMed ID: 10717909)
1. Toxicity of high-activity 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours.
Caplin ME; Mielcarek W; Buscombe JR; Jones AL; Croasdale PL; Cooper MS; Burroughs AK; Hilson AW
Nucl Med Commun; 2000 Jan; 21(1):97-102. PubMed ID: 10717909
[TBL] [Abstract][Full Text] [Related]
2. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
Krenning EP; de Jong M; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; Jamar F; Pauwels S; Valkema R
Ann Oncol; 1999; 10 Suppl 2():S23-9. PubMed ID: 10399029
[TBL] [Abstract][Full Text] [Related]
3. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience.
Valkema R; De Jong M; Bakker WH; Breeman WA; Kooij PP; Lugtenburg PJ; De Jong FH; Christiansen A; Kam BL; De Herder WW; Stridsberg M; Lindemans J; Ensing G; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):110-22. PubMed ID: 11965606
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
6. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
Bomanji JB; Papathanasiou ND
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
[TBL] [Abstract][Full Text] [Related]
7. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response.
Buscombe JR; Cwikla JB; Caplin ME; Hilson AJ
Nucl Med Commun; 2005 Nov; 26(11):969-76. PubMed ID: 16208174
[TBL] [Abstract][Full Text] [Related]
9. The role of radioactive somatostatin and its analogues in the control of tumor growth.
Krenning EP; Valkema R; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; de Jong M; Jamar F; Pauwels S
Recent Results Cancer Res; 2000; 153():1-13. PubMed ID: 10626285
[TBL] [Abstract][Full Text] [Related]
10. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine.
Rolleman EJ; Valkema R; de Jong M; Kooij PP; Krenning EP
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):9-15. PubMed ID: 12483404
[TBL] [Abstract][Full Text] [Related]
11. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
12. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
[TBL] [Abstract][Full Text] [Related]
13. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors.
Modlin IM; Cornelius E; Lawton GP
Arch Surg; 1995 Apr; 130(4):367-73; discussion 373-4. PubMed ID: 7710334
[TBL] [Abstract][Full Text] [Related]
14. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.
Wangberg B; Forssell-Aronsson E; Tisell LE; Nilsson O; Fjalling M; Ahlman H
Br J Cancer; 1996 Mar; 73(6):770-5. PubMed ID: 8611378
[TBL] [Abstract][Full Text] [Related]
15. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
16. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver.
Slooter GD; Breeman WA; Marquet RL; Krenning EP; van Eijck CH
Int J Cancer; 1999 May; 81(5):767-71. PubMed ID: 10328231
[TBL] [Abstract][Full Text] [Related]
17. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.
Waldherr C; Pless M; Maecke HR; Haldemann A; Mueller-Brand J
Ann Oncol; 2001 Jul; 12(7):941-5. PubMed ID: 11521799
[TBL] [Abstract][Full Text] [Related]
18. Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effects.
Tiensuu Janson E; Eriksson B; Oberg K; Skogseid B; Ohrvall U; Nilsson S; Westlin JE
Acta Oncol; 1999; 38(3):373-7. PubMed ID: 10380830
[TBL] [Abstract][Full Text] [Related]
19. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
Otte A; Jermann E; Behe M; Goetze M; Bucher HC; Roser HW; Heppeler A; Mueller-Brand J; Maecke HR
Eur J Nucl Med; 1997 Jul; 24(7):792-5. PubMed ID: 9211767
[TBL] [Abstract][Full Text] [Related]
20. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]